Uraemic dyslipidaemia revisited: Role of high-density lipoprotein

Nephrology Dialysis Transplantation

Volumn 28, Issue 10, 2013, Pages 2456-2463

  Speer, Thimoteus ^a   Zewinger, Stephen ^a   Fliser, Danilo ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

cardiovascular disease; chronic kidney disease; endothelial dysfunction; high density lipoprotein

Indexed keywords

6 N,N' DIMETHYLARGININE; ABC TRANSPORTER G1; APOLIPOPROTEIN A1; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; PLACEBO; REACTIVE OXYGEN METABOLITE; TORCETRAPIB;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CELL PROTECTION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CHRONIC KIDNEY DISEASE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HUMAN; LIPID COMPOSITION; LIPOPROTEIN METABOLISM; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; TISSUE REPAIR; UREMIA; UREMIC DYSLIPIDEMIA;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; ENDOTHELIAL DYSFUNCTION; HIGH-DENSITY LIPOPROTEIN;

CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS, HDL; UREMIA;

EID: 84884943966     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft080     Document Type: Review

References (59)

1. Fox CS, Matsushita K, Woodward M et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012; 380: 1662-1673
2. Mahmoodi BK, Matsushita K, Woodward M et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a metaanalysis. Lancet 2012; 380: 1649-1661
3. Tonelli M, Muntner P, Lloyd A et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 2012; 380: 807-814
4. Gerstein HC, Mann JF, Yi Q et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426 (Pubitemid 32681484)
5. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
6. Van Biesen W, De Bacquer D, Verbeke F et al. The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J 2007; 28: 478-483 (Pubitemid 47343557)
7. Barter P, Gotto AM, LaRosa JC et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357: 1301-1310 (Pubitemid 47481452)
8. Lewington S, Whitlock G, Clarke R et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. Lancet 2007; 370: 1829-1839
9. Charakida M, Besler C, Batuca JR et al. Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA 2009; 302: 1210-1217
10. Sorrentino SA, Besler C, Rohrer L et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extendedrelease niacin therapy. Circulation 2010; 121: 110-122
11. Khera AV, Cuchel M, de la Llera-Moya M et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364: 127-135
12. Yamamoto S, Yancey PG, Ikizler TA et al. Dysfunctional highdensity lipoprotein in patients on chronic hemodialysis. J Am Coll Cardiol 2012; 60: 2372-2379
13. Yuhanna IS, Zhu Y, Cox BE et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 2001; 7: 853-857 (Pubitemid 32691642)
14. Assanasen C, Mineo C, Seetharam D et al. Cholesterol binding, efflux, and a PDZ-interacting domain of scavenger receptor-BI mediate HDL-initiated signaling. J Clin Invest 2005; 115: 969-977 (Pubitemid 40489401)
15. Dimmeler S, Fleming I, Fisslthaler B et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399: 601-605
16. Mineo C, Yuhanna IS, Quon MJ et al. High density lipoproteininduced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem 2003; 278: 9142-9149 (Pubitemid 36800395)
17. Nofer JR, van der Giet M, Tolle M et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 2004; 113: 569-581 (Pubitemid 38542506)
18. Theilmeier G, Schmidt C, Herrmann J et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 2006; 114: 1403-1409 (Pubitemid 44454560)
19. Terasaka N, Yu S, Yvan-Charvet L et al. ABCG1 and HDL protect against endothelial dysfunction in mice fed a highcholesterol diet. J Clin Invest 2008; 118: 3701-3713
20. Spieker LE, Sudano I, Hurlimann D et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002; 105: 1399-1402 (Pubitemid 34263266)
21. Mineo C, Deguchi H, Griffin JH et al. Endothelial and antithrombotic actions of HDL. Circ Res 2006; 98: 1352-1364 (Pubitemid 43948059)
22. Cockerill GW, Rye KA, Gamble JR et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995; 15: 1987-1994
23. Patel S, Di Bartolo BA, Nakhla S et al. Anti-inflammatory effects of apolipoprotein A-I in the rabbit. Atherosclerosis 2010; 212: 392-397
24. Murphy AJ, Woollard KJ, Hoang A et al. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol 2008; 28: 2071-2077
25. Kimura T, Tomura H, Mogi C et al. Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J Biol Chem 2006; 281: 37457-37467 (Pubitemid 46042049)
26. Dimmeler S, Haendeler J, Zeiher AM. Regulation of endothelial cell apoptosis in atherothrombosis. Curr Opin Lipidol 2002; 13: 531-536 (Pubitemid 35231933)
27. Kimura T, Sato K, Malchinkhuu E et al. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler Thromb Vasc Biol 2003; 23: 1283-1288 (Pubitemid 36871285)
28. Nofer JR, Levkau B, Wolinska I et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDLassociated lysosphingolipids. J Biol Chem 2001; 276: 34480-5
29. Suc I, Escargueil-Blanc I, Troly M et al. HDL and ApoA prevent cell death of endothelial cells induced by oxidized LDL. Arterioscler Thromb Vasc Biol 1997; 17: 2158-2166 (Pubitemid 28057117)
30. Sugano M, Tsuchida K, Makino N. High-density lipoproteins protect endothelial cells from tumor necrosis factor-alphainduced apoptosis. Biochem Biophys Res Commun 2000; 272: 872-876 (Pubitemid 30420728)
31. Niimi Y, Azuma H, Hirakawa K. Repeated endothelial removal augments intimal thickening and attenuates EDRF release. Am J Physiol 1994; 266: H1348-H1356
32. Bahlmann FH, Speer T, Fliser D. Endothelial progenitor cells in chronic kidney disease. Nephrol Dial Transplant 2010; 25: 341-346
33. Fadini GP, Losordo D, Dimmeler S. Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ Res 2012; 110: 624-637
34. Schmidt-Lucke C, Rossig L, Fichtlscherer S et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005; 111: 2981-2987 (Pubitemid 40814192)
35. Werner N, Kosiol S, Schiegl T et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353: 999-1007 (Pubitemid 41262334)
36. Murugesan G, Sa G, Fox PL. High-density lipoprotein stimulates endothelial cell movement by a mechanism distinct from basic fibroblast growth factor. Circ Res 1994; 74: 1149-1156 (Pubitemid 24176910)
37. Tamagaki T, Sawada S, Imamura H et al. Effects of high-density lipoproteins on intracellular pH and proliferation of human vascular endothelial cells. Atherosclerosis 1996; 123: 73-82 (Pubitemid 26175069)
38. Tauber JP, Cheng J, Massoglia S et al. High density lipoproteins and the growth of vascular endothelial cells in serum-free medium. In Vitro 1981; 17: 519-530 (Pubitemid 12235258)
39. Seetharam D, Mineo C, Gormley AK et al. High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ Res 2006; 98: 63-72 (Pubitemid 43970204)
40. Feng Y, van Eck M, Van Craeyveld E et al. Critical role of scavenger receptor-BI-expressing bone marrow-derived endothelial progenitor cells in the attenuation of allograft vasculopathy after human apo A-I transfer. Blood 2009; 113: 755-764
41. Sumi M, Sata M, Miura S et al. Reconstituted high-density lipoprotein stimulates differentiation of endothelial progenitor cells and enhances ischemia-induced angiogenesis. Arterioscler Thromb Vasc Biol 2007; 27: 813-818 (Pubitemid 46606711)
42. Tso C, Martinic G, Fan WH et al. High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler Thromb Vasc Biol 2006; 26: 1144-1149 (Pubitemid 43732125)
43. Vaisar T, Pennathur S, Green PS et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007; 117: 746-756 (Pubitemid 46348533)
44. Holzer M, Birner-Gruenberger R, Stojakovic T et al. Uremia alters HDL composition and function. J Am Soc Nephrol 2011; 22: 1631-1641
45. Weichhart T, Kopecky C, Kubicek M et al. Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol 2012; 23: 934-947
46. Kalantar-Zadeh K, Kopple JD, Kamranpour N et al. HDLinflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int 2007; 72: 1149-1156 (Pubitemid 47609043)
47. Vaziri ND, Moradi H, Pahl MV et al. In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL proinflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Kidney Int 2009; 76: 437-444
48. Zheng L, Nukuna B, Brennan ML et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004; 114: 529-541 (Pubitemid 39572103)
49. Kraus LM, Kraus AP, Jr. Carbamoylation of amino acids and proteins in uremia. Kidney Int Suppl 2001; 78: S102-S107 (Pubitemid 32144080)
50. Wang Z, Nicholls SJ, Rodriguez ER et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007; 13: 1176-1184 (Pubitemid 47530630)
51. Holzer M, Gauster M, Pfeifer T et al. Protein carbamylation renders high-density lipoprotein dysfunctional. Antioxid Redox Signal 2011; 14: 2337-2346
52. Holzer M, Zangger K, El-Gamal D et al. Myeloperoxidasederived chlorinating species induce protein carbamylation through decomposition of thiocyanate and urea: novel pathways generating dysfunctional high-density lipoprotein. Antioxid Redox Signal 2012; 17: 1043-1052
53. Speer T, Rohrer L, Blyszczuk P et al. Abnormal High-Density Lipoprotein Induces Endothelial Dysfunction via Activation of Toll-Like Receptor-2. Immunity 2013; http://dx.doi.org/10.1016/j.immuni.2013.02.009
54. Bode-Boger SM, Scalera F, Kielstein JT et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol 2006; 17: 1128-1134
55. Kielstein JT, Salpeter SR, Bode-Boeger SM et al. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function- a meta-analysis. Nephrol Dial Transplant 2006; 21: 2446-2451 (Pubitemid 44644516)
56. Boden WE, Probstfield JL, Anderson T et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255-2267
57. Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-2122 (Pubitemid 350146106)
58. Schwartz GG, Olsson AG, Abt M et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367: 2089-2099
59. Luscher TF, Taddei S, Kaski JC et al. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J 2012; 33: 857-865